<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">Endothelial dysfunction</z:e> is considered an important early marker of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and cardiovascular risk and is currently used as a surrogate end point for cardiovascular risk in clinical trials </plain></SENT>
<SENT sid="1" pm="."><plain>Type 2 diabetic patients show a characteristic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Aggressive <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering might be an effective method to improve endothelial function in these patients </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: A randomized, double-blind, placebo-controlled trial was completed to study the effect of 30 weeks' administration of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg and 80 mg on endothelial function, as assessed by B-mode ultrasound of the brachial artery, in 133 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> without a history of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> had considerable endothelium-dependent and endothelium-independent dysfunction; mean flow-mediated vasodilation (SD) was 3.16% (3.56), and mean response on sublingual <z:chebi fb="0" ids="28787">nitroglycerin</z:chebi> was 6.58% (6.04) </plain></SENT>
<SENT sid="5" pm="."><plain>Despite substantial lowering of <z:hpo ids='HP_0000001'>all</z:hpo> atherogenic <z:chebi fb="23" ids="18059">lipid</z:chebi> parameters, no improvement of endothelium-dependent vasodilatation was found (P &gt; 0.8) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: We observed considerable baseline endothelium-dependent and endothelium-independent dysfunction in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> without a history of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Aggressive <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering by administration of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, resulting in substantial improvement of the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, did not reverse <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
</text></document>